

Application No. 10/762,616
Amdt. dated 4 June 2010
Reply to Office Action of 16 March 2010

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A pharmaceutical composition for the oral administration ~~of~~including tinidazole and fluconazole or a stereoisomer or a stereoisomeric uniform mixture thereof, comprising a single tablet having from about 50 to less than 150 mg fluconazole and from about 1000 to less than 2000 mg tinidazole for use as a unit dose.

2. (currently amended) A pharmaceutical composition characterized by secnidazole and fluconazole or a stereoisomer or a stereoisomeric mixture thereof, comprising a unit dosage of a single tablet for oral administration having a uniform mixture from about 50 to less than 150 mg of fluconazole and from about 1000 to less than 2000 mg of secnidazole.

3. (previously presented) The pharmaceutical composition according to Claim 2, characterized by a percent by weight of $75\% \pm 20\%$ secnidazole and a percent by weight of $6\% \pm 2\%$ fluconazole.

Claims 4 - 5. (cancelled)

6. (previously presented) The pharmaceutical composition according to Claim 2, characterized by a vehicle mixture of acceptable pharmaceutical vehicles that comprises microcrystalline cellulose, sodium glycolate of starch, polyvinylpyrrolidone, magnesium stearate and white opadry.

Claims 7-12 (cancelled)

13. (previously presented) The pharmaceutical composition according to Claim 1, characterized by a percent by weight of $75\% \pm 20\%$ tinidazole and a percent by weight of $6\% \pm 2\%$ fluconazole.

Claims 14-15. (cancelled)

16. (previously presented) The pharmaceutical composition according to Claim 1, characterized by a vehicle mixture of acceptable pharmaceutical vehicles that comprises microcrystalline cellulose, sodium glycolate of starch, polyvinylpyrrolidone, magnesium stearate and white opadry.

17. (previously presented) The pharmaceutical composition according to Claim 1, characterized by a percent by weight of 75% tinidazole.

18. (previously presented) The pharmaceutical composition according to Claim 2, characterized by a percent by weight of 75% secnidazole.

19. (previously presented) The pharmaceutical composition according to Claim 1, characterized by a percent by weight of 5.7% fluconazole.

20. (previously presented) The pharmaceutical composition according to Claim 2, characterized by a percent by weight of 5.7% fluconazole.

21. (previously presented) The pharmaceutical composition according to Claim 1, wherein the composition is characterized by about 112.5 mg of fluconazole and about 1.5 g of tinidazole.

Application No. 10/762,616
Amdt. dated 4 June 2010
Reply to Office Action of 16 March 2010

22. (previously presented) The pharmaceutical composition according to Claim 2, wherein the composition is characterized by about 112.5 mg of fluconazole and about 1.5 g of secnidazole.